Prothena Public Limited (PRTA) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Prothena Corporation Public Limited Company  (NASDAQ: PRTA)

Prothena Public Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Prothena Public Limited in the second quarter 2026?
Prothena Corporation Public Limited Company recorded a cumulative net loss of $-44 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -14.98%.

Within the Major Pharmaceutical Preparations industry 87 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1944 to 3221.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -11.54 % -28.57 % -42.4 % -44.8 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -44 -151 -244 -280 -303
Return On Equity (TTM) -14.98 % -49.88 % -73 % -72.66 % -67.95 %
PRTA's Total Ranking # 3221 # 1944 # 2407 # 3080 # 2862
Equity (TTM) in Millions 287 313 280 295 324
Seq. Equity Change -8.23 % 11.46 % -4.92 % -9.05 % -25.9 %
Seq. Net Income Change - - - - -

Back to PRTA Management Effectiveness >> PRTA's 5 Years Annual ROE >> Compare PRTA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 88
Sector # 256
Overall # 3221

Return On Equity Statistics
High Average Low
23.2 %
-27.62 %
-73 %
(Sep 30 2021)   (Dec 31 2025)





PRTA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 280 487 561 622 466
Y / Y Equity Change -42.4 % -13.26 % -9.75 % 33.47 % 153.28 %
Net Income in Millions -244 -122 -147 -117 67
Y / Y Net Income Change - - - - -
Return On Equity -87.03 % -25.12 % -26.19 % -18.8 % 14.37 %

Back to PRTA Management Effectiveness >> PRTA's 5 Years Annual ROE >> Compare PRTA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PRTA's' Return on Equity at Yahoo Finance
PRTA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PRTA's Competitors
Subscribers only: Roe for Prothena Public Limited's Suppliers
Subscribers only: Return On Equity for PRTA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-08T21:44:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.